Should You Buy Novavax on the Dip?

Novavax (NASDAQ: NVAX) soared to stardom last year as investors bet on the prospects of its coronavirus vaccine candidate. As a result, the stock surged 2,700% in 2020.

Novavax shares have increased this year, but a lot less -- about 80%. Why? Investors lost patience with the company. Manufacturing and raw materials issues have delayed Novavax's submission for Emergency Use Authorization to the Food and Drug Administration. Now a new issue is arising. This week, investors started worrying about the post-pandemic outlook for vaccine sales. Novavax stock lost 20% in four trading sessions. Should you flee the stock -- or should you buy on the dip?

Image source: Getty Images.

Continue reading

Source Fool.com